| Recruiting | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer | Phase 1 / Phase 2 | 2025-06-24 |
| Active Not Recruiting | A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients Low Grade Serous Ovarian Cancer, Ovarian Cancer | Phase 2 | 2024-10-30 |
| Recruiting | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer Low Grade Serous Ovarian Cancer | Phase 3 | 2024-03-18 |
| Active Not Recruiting | Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Ca KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer | Phase 1 / Phase 2 | 2023-03-22 |
| Active Not Recruiting | Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer | Phase 1 / Phase 2 | 2022-08-01 |
| Active Not Recruiting | Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients Non Small Cell Lung Cancer, KRAS Activating Mutation | Phase 1 / Phase 2 | 2022-04-12 |
| Completed | Food Effect of VS-6766 in Healthy Adult Subjects Food Effect | Phase 1 | 2021-12-16 |
| Completed | A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Non Small Cell Lung Cancer, KRAS Activating Mutation | Phase 2 | 2020-12-31 |
| Active Not Recruiting | A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer | Phase 2 | 2020-12-21 |
| Terminated | Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defac Epithelial Ovarian Cancer | Phase 1 | 2016-10-01 |
| Terminated | Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Pancreatic Cancer | Phase 1 | 2015-09-01 |
| Completed | A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male S Healthy Subjects | Phase 1 | 2015-08-01 |
| Terminated | A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Relapsed Malignant Mesothelioma | Phase 1 | 2015-01-01 |
| Terminated | Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Part Malignant Pleural Mesothelioma | Phase 2 | 2013-12-12 |
| Terminated | Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma Non Hematologic Cancers, Metastatic Cancer, Lymphoma | Phase 1 | 2013-11-01 |
| Completed | Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies Non Hematologic Cancers | Phase 1 | 2013-09-02 |
| Completed | Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer Non Small Cell Lung Cancer, Lung Cancer | Phase 2 | 2013-09-01 |
| Terminated | Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma | Phase 2 | 2013-09-01 |
| Terminated | Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies Non Hematologic Cancers, Metastatic Cancer | Phase 1 | 2013-06-01 |
| Completed | Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer Ovarian Cancer | Phase 1 | 2013-02-26 |
| Completed | A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies Cancer | Phase 1 | 2008-12-01 |
| Completed | Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms Head and Neck Neoplasm, Prostatic Neoplasm, Pancreatic Neoplasm | Phase 1 | 2005-12-01 |
| Withdrawn | Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia | Phase 1 | — |